Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07492680 | A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) | PHASE2 | NOT YET_RECRUITING | 260 | — | — | Jul 17, 2026 | May 20, 2032 | May 29, 2026 | 58 | United States, Belgium +11 |
OR is defined as confirmed complete response (CR) or partial response (PR) by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, Response Assessment in Neuro-Oncology (RANO) v2 or Modified RECIST v1.1
| Arm | Type | Description |
|---|---|---|
| Part 1a | EXPERIMENTAL | BMS-986504 |
| Part 1b | EXPERIMENTAL | BMS-986504 |
| Part 2: Cohort 1 | EXPERIMENTAL | BMS-986504 + Pumitamig + Chemotherapy |
| Part 2: Cohort 2a | EXPERIMENTAL | BMS-986504 + Daraxonrasib |
| Part 2: Cohort 2b | EXPERIMENTAL | BMS-986504 + Daraxonrasib |
| Part 2: Cohort 2c | EXPERIMENTAL | BMS-986504 + Daraxonrasib + Chemotherapy |
| Part 2: Cohort 3 | EXPERIMENTAL | BMS-986504 + Nivolumab + Relatlimab FDC |
| Part 2: Cohort 4 | EXPERIMENTAL | BMS-986504 + Temozolomide + Radiotherapy |
| Name | Type | Description |
|---|---|---|
| BMS-986504 | DRUG | Specified dose on specified days |
| Daraxonrasib | DRUG | Specified dose on specified days |
| Nivolumab + Relatlimab FDC | DRUG | Specified dose on specified days |
| Temozolomide | DRUG | Specified dose on specified days |
| Pumitamig | DRUG | Specified dose on specified days |
| Pemetrexed | DRUG | Specified dose on specified days |
| Carboplatin | DRUG | Specified dose on specified days |
| Nab-paclitaxel | DRUG | Specified dose on specified days |
| Gemcitabine | DRUG | Specified dose on specified days |
| Paclitaxel | DRUG | Specified dose on specified days |
Inclusion Criteria: * Participant must have histologically confirmed diagnosis of advanced and/or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene detected in tumor tissue. * Depending on the cohort enrolled, participants must have received standard therapies appropriate ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab, V503, GARDASIL |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| AstraZeneca PLC | AZN | 1 | — | Trastuzumab deruxtecan |